Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01725113 · ClinicalTrials.gov registry record · Phase 4
Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol
A Phase 4 study, sponsored by Winthrop University Hospital.
- Terminated
- Registry status
- Phase 4
- Development phase
- 16
- Enrollment target
NCT01725113: Clinical Trial Phase 4 study, sponsored by Winthrop University Hospital.
NCT01725113 is a Phase 4 study that was terminated before completion, run by Winthrop University Hospital. The registered enrollment target is 16 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01725113, a Phase 4 study, was terminated before completion, sponsored by Winthrop University Hospital.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this non-inferiority study is to compare the safety and effectiveness of a mineral and bone disease treatment protocol based on calcitriol to one based on paricalcitol in hemodialysis patients using revised Kidney Disease: Improving Global Outcomes (KDIGO) parathyroid hormone targets.
Interventions
- DRUG Paricalcitol
- DRUG Calcitriol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2012-11 |
| Est. Completion | 2015-10 |
| Phase | Phase 4 |
Why NCT01725113 stopped before completion
NCT01725113 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Paricalcitol is the first listed.
NCT01725113 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01725113 about?
NCT01725113 is a clinical study titled "Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol". The purpose of this non-inferiority study is to compare the safety and effectiveness of a mineral and bone disease treatment protocol based on calcitriol to one based on paricalcitol in hemodialysis patients using revised Kidney Disease: Improving Global Outcomes (KDIGO) parathyroid hormone targets.
What is the current status of trial NCT01725113?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 16 participants. The study started on 2012-11. Estimated completion is 2015-10.
What interventions are being tested in trial NCT01725113?
The interventions under investigation include: Paricalcitol (DRUG), Calcitriol (DRUG).
Who is sponsoring clinical trial NCT01725113?
This trial is sponsored by Winthrop University Hospital, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01725113's enrollment target sits among peer trials
16 1869th of 2000 higher than 121 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia